Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2007

View Archived Issues

Novel treatment options for cancer outlined in recent patent literature

New agents for psychopharmacologic disorders described in recent patents

Clera patent discloses novel imaging agents for Parkinson's disease

AstraZeneca announces second quarter 2007 results

Novavax initiates clinical trial for VLP-based influenza vaccine

Ovation begins clinical trial of i.v. carbamazepine for epilepsy

Valeant completes enrollment of first retigabine pivotal phase III study

Orphan drug designation of LX-211 recommended by EMEA committee

Mecamylamine augmentation for the treatment of depression

First-in-man study of a compound targeting CENP-E

Ovarian cancer vaccine stimulates immune response in a phase I trial

MacroGenics initiates three clinical trials with teplizumab in type 1 diabetes

Univ. Birmingham selects Eden Biodesign to develop and produce novel autoimmune disease drug

ORG-26576 enhanced AMPA receptor function and increased working memory in animal studies

Genta and Emisphere submit IND for oral G-4544 formulation

Tobira completes Series A financing and licenses rights to Takeda anti-HIV compounds

Nuvelo reduces workforce and readjusts development programs

Rosetta Genomics and Ben Gurion University to collaborate on microRNA-based applications

Advanced Cell Technology and Mytogen enter merger agreement

OncoGenex begins enrollment for OGX-427 phase I trial for cancer

Enzon enrolls patients in PEG-SN38 phase I study for solid tumors or lymphoma

MedImmune begins phase IIa trial of MEDI-528 for asthma

Rheoscience and Dr. Reddy's begin phase III study of balaglitazone

New HIV Tat vaccine induces humoral and cell-mediated immune responses in mice

Interim results show improved lipid profiles in HIV patients treated with boosted Invirase

FDA approves Indevus's Sanctura XR for once-daily treatment of OAB

Health Canada approves GW and Bayer's Sativex for cancer pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...